Search results

778 results

Sorted by Relevance . Sort by Date

In development Remove In development filter
Proposed Remove Proposed filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
NICE guidelines Remove NICE guidelines filter
Diagnostics guidance Remove Diagnostics guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter

Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]

Proposed [GID-TA10774] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]

Proposed [GID-TA10775] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]

Proposed [GID-TA10776] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]

Proposed [GID-TA10777] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]

Proposed [GID-TA10778] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

Proposed [GID-TA10779] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]

Proposed [GID-TA10536] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

Proposed [GID-TA10757] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]

Proposed [GID-TA10758] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]

Proposed [GID-TA10741] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

Proposed [GID-TA10723] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839]

Proposed [GID-TA10725] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]

Proposed [GID-TA10726] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

Proposed [GID-TA10431] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]

Proposed [GID-TA10632] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Odevixibat (A 4250) for progressive familial intrahepatic cholestasis [ID1570]

Proposed [GID-TA10704] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remdesivir for treating COVID-19 [ID3808]

Proposed [GID-TA10721] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]

Proposed [GID-TA10691] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]

Proposed [GID-TA10694] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Retifanlimab for treating advanced anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]

Proposed [GID-TA10698] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Etranacogene dezaparvovec for treating haemophilia B [ID3812]

Proposed [GID-TA10699] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

Proposed [GID-TA10702] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eptinezumab for preventing migraine [ID3803]

Proposed [GID-TA10677] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Gefapixant for treating refractory chronic cough [ID3789]

Proposed [GID-TA10678] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remimazolam for general anaesthesia [ID3796]

Proposed [GID-TA10679] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]

Proposed [GID-TA10680] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]

Proposed [GID-TA10682] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

Proposed [GID-TA10684] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

Proposed [GID-TA10683] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]

Proposed [GID-TA10552] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps [ID3817]

Proposed [GID-TA10701] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Icosapent ethyl for reducing the risk of cardiovascular events due to hypertriglyceridemia [ID3831]

Proposed [GID-TA10736] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]

Proposed [GID-TA10676] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

Proposed [GID-TA10763] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]

Proposed [GID-TA10733] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]

Proposed [GID-TA10660] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer(CDF review TA528) [ID1644]

Proposed [GID-TA10782] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

Proposed
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF review of TA505) [ID1635]

Proposed [GID-TA10781] Expected publication date: 22 September 2021

Type

Technology appraisal guidance

Status

Proposed
Liposomal bupivacaine for treating postoperative pain [ID3799]

Proposed [GID-TA10681] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

Proposed [GID-TA10720] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

Proposed [GID-TA10605] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ibalizumabtreating for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]

Proposed [GID-TA10657] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]

Proposed [GID-TA10655] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

Proposed [GID-TA10764] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Semaglutide for managing overweight and obesity [ID3850]

Proposed [GID-TA10765] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

In development [GID-NG10141] Expected publication date: 17 November 2021

Type

NICE guideline

Status

In development
Epilepsies in children, young people and adults

In development [GID-NG10112] Expected publication date: 16 November 2021

Type

NICE guideline

Status

In development
Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)

In development [GID-NG10110] Expected publication date: TBC

Type

NICE guideline

Status

In development
Looked-after children and young people

In development [GID-NG10121] Expected publication date: 27 September 2021

Type

NICE guideline

Status

In development
Osteoarthritis: care and management (update)

In development [GID-NG10127] Expected publication date: 10 August 2022

Type

NICE guideline

Status

In development